Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Tango Therapeutics is seeking a visionary and strategic oncology leader to serve as Executive Director, Clinical Development. Reporting directly to the President of Research & Development, this highly visible executive will lead the clinical development strategy for an early-stage program.
As a senior clinical and scientific leader, you will partner with Translational Medicine, Biometrics, Clinical Pharmacology, Regulatory, Medical Affairs, and Executive Leadership driving cross-functional alignment, prioritization, and operational excellence. You will serve as an external facing ambassador for Tango, representing the company within the scientific and medical communities.
This role offers the opportunity to shape enterprise-wide clinical development strategy, build high-performing development capabilities, and play a pivotal role in advancing transformational therapies for patients with cancer.
Your Role:
As Executive Director, Clinical Development, you will provide strategic leadership for the development of TNG456. Working closely with cross-functional leaders, you will together be responsible execution of clinical studies and enable informed portfolio decisions. You will represent Tango within the external oncology community to advance innovative therapies for patients with cancer. You will manage, mentor and develop Medical Directors supporting TNG456.
What You Bring:
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.
Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
